# EDGAR Filing Document

**Accession Number:** 0001534120
**File Stem:** 0001104659-26-032997
**Filing Date:** 2026-3
**Character Count:** 23865
**Document Hash:** 5fa3fdfafdcadee5b7f822038b1af46c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-032997.hdr.sgml**: 20260323

**ACCESSION NUMBER**: 0001104659-26-032997

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 13

**FILED AS OF DATE**: 20260323

**DATE AS OF CHANGE**: 20260323

**EFFECTIVENESS DATE**: 20260323

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Avalo Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001534120
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 450705648
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294513
- **FILM NUMBER:** 26779879

**BUSINESS ADDRESS:**
- **STREET 1:** 1500 LIBERTY RIDGE DRIVE
- **STREET 2:** SUITE 321
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** 410-522-8707

**MAIL ADDRESS:**
- **STREET 1:** 1500 LIBERTY RIDGE DRIVE
- **STREET 2:** SUITE 321
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cerecor Inc.
- **DATE OF NAME CHANGE:** 20111102

**As filed with the Securities and Exchange Commission on March 23, 2026**

**Registration Statement No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**Avalo Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **45-0705648** |
| (State or other Jurisdiction | (I.R.S. employer identification number) |
| of Incorporation or Organization) |  |
| **1500 Liberty Ridge Drive, Suite 321**<br> **Wayne, Pennsylvania 19087** | **1500 Liberty Ridge Drive, Suite 321**<br> **Wayne, Pennsylvania 19087** |
| (Address, including zip code, of registrant's principal executive offices) | (Address, including zip code, of registrant's principal executive offices) |

---

**Avalo Therapeutics, Inc. Fourth Amended and Restated 2016 Equity Incentive Plan**

**Avalo Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase Plan**

(Full title of the plans)

**Christopher Sullivan, Chief Financial Officer**

**Avalo Therapeutics, Inc.**

**1500 Liberty Ridge Drive, Suite 321**

**Wayne, Pennsylvania 19087**

**(410) 522-8707**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

COPIES TO:

**Rachael Bushey, Esq.**<br> **Jennifer Porter, Esq.**<br> **Goodwin Procter LLP**<br> **3025 John F. Kennedy Boulevard, 8<sup>th</sup> Floor**<br> **Philadelphia, PA 19104**<br> **(445) 207-7800**<br>

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻ Accelerated filer ◻ <br> Non-accelerated filer ⌧ Smaller reporting company ⌧ <br> Emerging Growth Company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

This Registration Statement is being filed to register:

&nbsp;&nbsp;&nbsp;&nbsp;· an additional 1,865,256 shares of common stock
issuable pursuant to the Avalo Therapeutics, Inc. (the "Registrant") Fourth Amended and Restated 2016 Equity Incentive
Plan (the "2016 Stock Plan"); and

&nbsp;&nbsp;&nbsp;&nbsp;· an additional 373,051 shares of common stock
of the Registrant pursuant to the Avalo Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase Plan (the "ESPP");

all of which are securities of the same class for which Registration Statements on Form S-8 are effective. Accordingly, the contents of the previous Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the "Commission") on [May 20, 2016 (File No. 333-211490)](https://www.sec.gov/Archives/edgar/data/1534120/000155837016006099/cerc-20160520xs8.htm), [May 20, 2016 (File No. 333-211491)](https://www.sec.gov/Archives/edgar/data/1534120/000155837016006101/cerc-20160520xs8.htm), [August 10, 2018 (File No. 333-226767)](https://www.sec.gov/Archives/edgar/data/1534120/000162828018010996/s-8cerecoraugust102018.htm), [August 6, 2020 (File No. 333-241661)](https://www.sec.gov/Archives/edgar/data/1534120/000162828020012000/s-8cerecoraugust62020.htm), [May 13, 2021 (File No. 333-256082)](https://www.sec.gov/Archives/edgar/data/1534120/000162828021010153/cerecor-formsx82021eipever.htm), [May 13, 2021 (File No. 333-256083)](https://www.sec.gov/Archives/edgar/data/1534120/000162828021010154/cerecor-formsx82021espp.htm), [November 7, 2022 (File No. 333-268199)](https://www.sec.gov/Archives/edgar/data/1534120/000162828022028540/avtx-formsx82022eipesppeve.htm), [May 4, 2023 (File No. 333-271655)](https://www.sec.gov/Archives/edgar/data/1534120/000162828023015818/avtx-formsx82023eipesppeve.htm), [November 7, 2024 (File No. 333-283047)](https://www.sec.gov/Archives/edgar/data/1534120/000162828024045982/avtx-formsx82024eipespp.htm), [May 12, 2025 (File No. 333-287175)](https://www.sec.gov/Archives/edgar/data/1534120/000162828025024440/avtx-formsx82025eipespp.htm), [May 12, 2025 (File No. 333-287176)](https://www.sec.gov/Archives/edgar/data/1534120/000162828025024441/avtx-formsx82025inducement.htm), and [November 6, 2025 (File No. 333-291304)](https://www.sec.gov/Archives/edgar/data/1534120/000153412025000020/avtx-formsx82025inducement.htm) including periodic and current reports filed after the previous Registration Statements on Form S-8 to maintain current information about the Registrant, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

The additional shares are the result of the annual automatic increase provision of the 2016 Stock Plan and the ESPP.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8.** **Exhibits.**

The following exhibits are filed as part of this Registration Statement:

---

| | |
|:---|:---|
| Exhibit <br> No. | Description |
| [4.1](https://www.sec.gov/Archives/edgar/data/1534120/000110465918034094/a18-13783_1ex3d1d2.htm) | [Amended and Restated Certificate of Incorporation of Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1.2 to the Registrant's Current Report on Form 8-K filed with the Commission on May 17, 2018).](https://www.sec.gov/Archives/edgar/data/1534120/000110465918034094/a18-13783_1ex3d1d2.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1534120/000162828021017637/ex31_charteramendment-name.htm) | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on August 26, 2021).](https://www.sec.gov/Archives/edgar/data/1534120/000162828021017637/ex31_charteramendment-name.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/1534120/000162828022018705/ex-31_certificateofamendme.htm) | [Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on July 7, 2022).](https://www.sec.gov/Archives/edgar/data/1534120/000162828022018705/ex-31_certificateofamendme.htm) |
| [4.4](https://www.sec.gov/Archives/edgar/data/1534120/000162828023042817/ex-31_certificateofamendme.htm) | [Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on December 28, 2023).](https://www.sec.gov/Archives/edgar/data/1534120/000162828023042817/ex-31_certificateofamendme.htm) |
| [4.5](https://www.sec.gov/Archives/edgar/data/1534120/000162828024013786/ex-32fifthamendedandrestat.htm) | [Avalo Therapeutics, Inc. Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant's Annual Report on Form 10-K filed with the Commission on March 20, 2025).](https://www.sec.gov/Archives/edgar/data/1534120/000162828024013786/ex-32fifthamendedandrestat.htm) |
| [5.1\*](tm268193d1_ex5-1.htm) | [Opinion of Goodwin Procter LLP.](tm268193d1_ex5-1.htm) |
| [10.1](https://www.sec.gov/Archives/edgar/data/1534120/000162828024037174/ex-1014thamendedrestatedeip.htm) | [Avalo Therapeutics, Inc. Fourth Amended and Restated 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on August 14, 2024).](https://www.sec.gov/Archives/edgar/data/1534120/000162828024037174/ex-1014thamendedrestatedeip.htm) |
| [10.2](https://www.sec.gov/Archives/edgar/data/1534120/000162828024037174/ex-102amendedrestatedespp.htm) | [Avalo Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed with the Commission on August 14, 2024).](https://www.sec.gov/Archives/edgar/data/1534120/000162828024037174/ex-102amendedrestatedespp.htm) |
| [10.3](https://www.sec.gov/Archives/edgar/data/1534120/000153412025000018/ex-102avtxx2025inducementa.htm) | [Avalo Therapeutics, Inc. 2025 Inducement Award Plan (incorporated by reference to Exhibit 10.2 to the Current Report on Form 10-Q filed on November 6, 2025).](https://www.sec.gov/Archives/edgar/data/1534120/000153412025000018/ex-102avtxx2025inducementa.htm) |
| [23.1\*](tm268193d1_ex23-1.htm) | [Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.](tm268193d1_ex23-1.htm) |
| [23.2\*](tm268193d1_ex5-1.htm) | [Consent of Goodwin Procter LLP (included in Exhibit 5.1).](tm268193d1_ex5-1.htm) |
| [24.1\*](#a_001) | [Power of Attorney (included on signature page to this Registration Statement on Form S-8).](#a_001) |
| [107\*](tm268193d1_ex-filingfees.htm) | [Filing Fee Table.](tm268193d1_ex-filingfees.htm) |

---

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wayne, State of Pennsylvania, on the 23<sup>rd</sup> day of March, 2026.

---

| | |
|:---|:---|
| **AVALO THERAPEUTICS, INC.** | **AVALO THERAPEUTICS, INC.** |
| By: | /s/ Christopher Sullivan |
| Name: | Christopher Sullivan |
| Title: | Chief Financial Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Garry A. Neil and Christopher Sullivan, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Capacity** | **Date** |
| /s/ Garry A. Neil, M.D. | Chief Executive Officer and Director | March 23, 2026 |
| **Garry A. Neil, M.D.** | (*Principal Executive Officer*) |  |
| /s/ Christoper Sullivan | Chief Financial Officer | March 23, 2026 |
| **Christopher Sullivan** | (*Principal Financial and Accounting Officer*) |  |
| /s/ Michael Heffernan | Director and Chairman | March 23, 2026 |
| **Michael Heffernan** |  |  |
| /s/ Mitchell Chan | Director | March 23, 2026 |
| **Mitchell Chan** |  |  |
| /s/ Jonathan Goldman, M.D. | Director | March 23, 2026 |
| **Jonathan Goldman, M.D.** |  |  |
| /s/ Rita Jain, M.D. | Director | March 23, 2026 |
| **Rita Jain, M.D.** |  |  |
| /s/ Aaron Kantoff | Director | March 23, 2026 |
| **Aaron Kantoff** |  |  |
| /s/ Gilla Kaplan, Ph.D. | Director | March 23, 2026 |
| **Gilla Kaplan, Ph.D.** |  |  |
| /s/ Kevin Lind | Director | March 23, 2026 |
| **Kevin Lind** |  |  |
| /s/ Samantha Truex | Director | March 23, 2026 |
| **Samantha Truex** |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

March 23, 2026

Avalo Therapeutics, Inc.

1500 Liberty Ridge Drive, Suite 321

Wayne, Pennsylvania 19087

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as your counsel in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 2,238,307 shares (the "Shares") of Common Stock, par value $0.001 per share ("Common Stock"), of Avalo Therapeutics, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's Fourth Amended and Restated 2016 Equity Incentive Plan and Amended and Restated 2016 Employee Stock Purchase Plan (collectively, the "Plans").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

For purposes of the opinion set forth below, we have assumed that, at the time Shares are issued, the total number of then unissued Shares, when added to the number of shares of Common Stock issued, subscribed for, or otherwise committed to be issued, does not exceed the number of shares of Common Stock authorized by the Company's certificate of incorporation.

The opinion set forth below is limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

/s/ Goodwin Procter LLP

GOODWIN PROCTER LLP

## Exhibit 23.1

**Exhibit 23.1**

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Avalo Therapeutics, Inc. Fourth Amended and Restated 2016 Equity Incentive Plan and the Avalo Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase Plan of our report dated March 23, 2026, with respect to the consolidated financial statements of Avalo Therapeutics, Inc. and subsidiaries included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Jericho, New York

March 23, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Avalo Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.001 par value per share | Other | 1865256 | $15.77 | $29415087.12 | 0.0001381 | $4062.22 |
| 2 | Equity | Common Stock, $0.001 par value per share | Other | 373051 | $13.40 | $4998883.40 | 0.0001381 | $690.35 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $34413970.52  |  | $4752.57  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $4752.57  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 ("Registration Statement") shall also cover any additional shares of common stock, $0.001 par value per share (the "Common Stock") of Avalo Therapeutics, Inc. (the "Registrant") that become issuable under the Avalo Therapeutics, Inc. Fourth Amended and Restated 2016 Equity Incentive Plan (the "EIP") and the Avalo Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase Plan (the "ESPP") by reason of any stock dividend, stock split, recapitalization or any other similar transactions. (2) Represents an additional 1,865,256 shares of Common Stock reserved for issuance under the EIP as a result of an automatic increase effective January 1, 2026. Shares available for issuance under the EIP were previously registered on a Registration Statements on Form S-8 filed with the United States Securities and Exchange Commission ("SEC") on May 20, 2016 (File No. 333-211490), May 20, 2016 (File No. 333-211491), August 10, 2018 (File No. 333-226767), August 6, 2020 (File No. 333-241661), May 13, 2021 (File No. 333-256082), May 13, 2021 (File No. 333-256083), November 7, 2022 (File No. 333-268199), May 4, 2023 (File No. 333-271655), November 7, 2024 (File No. 333-283047), and May 12, 2025 (File No. 333-287175). (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act, and based on $15.77, the average of the high and low sale prices of the Common Stock as reported on Nasdaq on March 17, 2026 (such date being within five business days of the date that this Registration Statement was filed with the SEC).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 ("Registration Statement") shall also cover any additional shares of common stock, $0.001 par value per share (the "Common Stock") of Avalo Therapeutics, Inc. (the "Registrant") that become issuable under the Avalo Therapeutics, Inc. Fourth Amended and Restated 2016 Equity Incentive Plan (the "EIP") and the Avalo Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase Plan (the "ESPP") by reason of any stock dividend, stock split, recapitalization or any other similar transactions. (4) Represents an additional 373,051 shares of Common Stock reserved for future issuance under the ESPP as a result of an automatic increase effective January 1, 2026. Shares available for issuance under the ESPP were previously registered on a Registration Statement on Form S-8 filed with the SEC on May 20, 2016 (File No. 333-211490), May 20, 2016 (File No. 333-211491), August 10, 2018 (File No. 333-226767), August 6, 2020 (File No. 333-241661), May 13, 2021 (File No. 333-256082), May 13, 2021 (File No. 333-256083), November 7, 2022 (File No. 333-268199), May 4, 2023 (File No. 333-271655), November 7, 2024 (File No. 333-283047), and May 12, 2025 (File No. 333-287175). (5) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act, and based on 85% (the percentage of the price per share applicable to purchases under the ESPP) of $15.77, the average of the high and low sale prices of the Common Stock as reported on Nasdaq on March 17, 2026 (such date being within five business days of the date that this Registration Statement was filed with the SEC).

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---